Weight Reduction in Overweight or Obese Individuals with Type 2 Diabetes after Treatment with Cagrilintid
Zusammenfassung der Studie
We are conducting this study to investigate how much the study drug called Cagrilintid reduces body weight in people with overweight or obesity and type 2 diabetes. Overweight or obesity is the condition in which the body stores too much fat. People with overweight or obesity and type 2 diabetes have a higher risk of other diseases such as heart disease and kidney disease. Weight loss reduces the risk of these diseases. Overweight and obesity can be treated through diet and physical activity, but this does not lead to weight loss for everyone. Cagrilintid could help people lose more weight than through diet and physical activity alone. Researchers will investigate this in this study. This study, which will last approximately 1 year and 6 months, will involve 330 men and women from around the world. Participants will be randomly assigned (by a computer) to 2 treatment groups: Cagrilintid will be compared to a placebo that looks like the tested drug but contains no active ingredients. During the study, patients will need to attend some visits to the study center and have phone contacts with the study staff. They will also need to undergo some tests and examinations as well as fill out questionnaires. The collected information may help to better understand: • Overweight, obesity, and type 2 diabetes or related diseases • How the study drug works in the body • How to improve the treatment of people with overweight, obesity, and type 2 diabetes or related diseases.
(BASEC)
Untersuchte Intervention
The aim of this study is to investigate the efficacy and safety of the amylin analogue Cagrilintide as a treatment for weight reduction in overweight or obese individuals with type 2 diabetes. The study will compare the effect of a once-weekly subcutaneously administered injection of Cagrilintide 2.4 mg with a placebo (which looks like the tested drug but contains no active ingredient).
(BASEC)
Untersuchte Krankheit(en)
Overweight or Obesity and Type 2 Diabetes
(BASEC)
1. Body mass index (BMI) ≥ 27.0 kg/m² and a history of at least one self-reported unsuccessful diet attempt for weight reduction. 2. Diagnosed with type 2 diabetes (T2D) for at least 180 days prior to screening. 3. Treatment either with a lifestyle intervention or: a) A stable treatment for at least 90 days prior to screening with 1-3 approved oral antidiabetic agents. b) For up to 30% of participants, treatment with a stable dose of a GLP-1 (glucagon-like peptide-1) containing medication that has been stable for at least 1 year prior to screening and/or treatment with basal insulin that has been stable for at least 90 days prior to screening is allowed. (BASEC)
Ausschlusskriterien
1. Treatment or intention to start treatment with a weight control medication within 180 days prior to screening. 2. Treatment with a GLP-1 receptor agonist or a medication containing GLP-1 within 180 days prior to screening, except for those who were randomized according to the inclusion criteria. 3. Previous dosing of marketed or non-marketed amylin-based compounds. (BASEC)
Studienstandort
Basel, Zürich, Andere
(BASEC)
Olten
(BASEC)
Sponsor
Novo Nordisk Pharma AG
(BASEC)
Kontakt für weitere Auskünfte zur Studie
Kontaktperson Schweiz
Maddalena Ghielmetti
+41 79 236 61 37
mdlg@clutternovonordisk.comNovo Nordisk Pharma AG The Circle 32/38 8058 Zürich
(BASEC)
Wissenschaftliche Auskünfte
nicht verfügbar
Name der bewilligenden Ethikkommission (bei multizentrischen Studien nur die Leitkommission)
Ethikkommission Nordwest- und Zentralschweiz EKNZ
(BASEC)
Datum der Bewilligung durch die Ethikkommission
29.10.2025
(BASEC)
ICTRP Studien-ID
nicht verfügbar
Offizieller Titel (Genehmigt von der Ethikkommission)
Efficacy and safety of cagrilintide for weight management in participants with overweight or obesity and type 2 diabetes (BASEC)
Wissenschaftlicher Titel
nicht verfügbar
Öffentlicher Titel
nicht verfügbar
Untersuchte Krankheit(en)
nicht verfügbar
Untersuchte Intervention
nicht verfügbar
Studientyp
nicht verfügbar
Studiendesign
nicht verfügbar
Ein-/Ausschlusskriterien
nicht verfügbar
nicht verfügbar
Primäre und sekundäre Endpunkte
nicht verfügbar
nicht verfügbar
Registrierungsdatum
nicht verfügbar
Einschluss des ersten Teilnehmers
nicht verfügbar
Sekundäre Sponsoren
nicht verfügbar
Weitere Kontakte
nicht verfügbar
Sekundäre IDs
nicht verfügbar
Angaben zur Verfügbarkeit von individuellen Teilnehmerdaten
nicht verfügbar
Weitere Informationen zur Studie
nicht verfügbar
Ergebnisse der Studie
Zusammenfassung der Ergebnisse
nicht verfügbar
Link zu den Ergebnissen im Primärregister
nicht verfügbar